Lupin, one of the leading pharmaceutical companies in India, announced today that it has received final approval for its Fenofibrate Tablets, 54 mg and 160 mg from the United States Food and Drugs Administration (USFDA) to market a generic version of Teva's Fenofibrate Tablets, 54 mg and 160 mg.

The company would commence promoting the product shortly in the US.

Lupin's Fenofibrate Tablets, 54 mg and 160 mg is the AB rated generic equivalent of the current reference listed drug, Fenofibrate Tablets, 54 mg and 160 mg of Teva.

Shares of the company gained Rs 96.75, or 5.39%, to settle at Rs 1,892.10. The total volume of shares traded was 294,541 at the BSE (Thursday).